This research trial studies characterization of T-cell repertoire through next-generation sequencing in patients with acute myeloid leukemia undergoing stem cell transplant. Characterizing T-cell repertoire may help to understand if immune system plays a significant role in high risk patients with acute myeloid leukemia.
Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC)
Inability to provide consent because of severe mental disorders
Donor unwilling to provide consent
Patients with AML scheduled to undergo HSCT
Case-only
Prospective
Biospecimen Collection
Procedure/SurgeryUndergo collection of blood samples
Laboratory Biomarker Analysis
Other interventionCorrelative studies
Time to diagnosis of acute graft versus (vs.) host disease (aGVHD)
Will be calculated as the time from stem cell infusion until the date of the diagnosis of aGVHD. If a patient dies prior to day 100 and does not have aGVHD, the patient will be censored at the time of death; all patients without aGVHD will be censored on day 100.
Time to diagnosis of relapse
Will be calculated as the time from stem cell infusion until the date of the of the diagnosis of relapse Patients who die of treatment toxicity or other cause, prior to relapse, will be censored at the time of death; all patients will be censored at 365 days following transplant.
Click on the lead sponsor to view all of their trials.
University of Southern California
Lead sponsor
National Cancer Institute (NCI)
Collaborator
